Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company